B
Bull
Bull · 25%CRGX
$6.05
Precio del escenario
$4.470
-0.069 (-1.54%)Al cierre
Loading chart…
- High
- 4.530
- Open
- 4.530
- VWAP
- 4.49
- Vol
- 10.92M
- Mkt Cap
- —
- Low
- 4.460
- Amount
- 48.99M
- EV/EBITDA, TTM
- 0.64
CARGO Therapeutics, Inc. is a biotechnology company focused on the development of best-in-class and potentially curative cell therapies for cancer patients. It has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer.
Métricas de valoración
The current forward P/E ratio for CARGO Therapeutics Inc (CRGX) is -1.74, compared to its 5-year average forward P/E of -3.46.
Alphio AI Price Scenarios for CRGX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
7.007-26GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX, WAT, CORZ on Behalf of Shareholders
7.007-14GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX, OLO, KLG, GNTY on Behalf of Shareholders
8.507-14GlobenewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CARGO Therapeutics, Inc. (Nasdaq - CRGX), Olo Inc. (NYSE - OLO), WK Kellogg Co (NYSE - KLG), Guaranty Bancshares, Inc. (NYSE - GNTY)
7.007-12GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, CRGX, HMST, PBBK on Behalf of Shareholders
7.007-11PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KLG, DALN, CRGX on Behalf of Shareholders
CRGX FAQ — answered by Alphio AI
CARGO Therapeutics, Inc. is a biotechnology company focused on the development of best-in-class and potentially curative cell therapies for cancer patients. It has a focused pipeline that includes its CRG-023 product candidate, a CD19/CD20/CD22 tri-specific CAR T developed using a tri-cistronic construct and designed to address several known causes of relapse, resulting in a potential best-in-class CAR T-cell therapy across a range of B-cell malignancies with the goal of providing more patients with a durable complete response. Its latest program advancement, an allogeneic platform, is a universal vector solution designed to limit immune-based rejection and enable durable response of CAR T-cell therapy. The universal allogeneic-enabling vector is intended to be paired with any CAR vector to create an allogeneic CAR T-cell therapy, with the potential to maintain the efficacy, durability, and safety of autologous cell therapy while broadening availability to more people with cancer. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.